Mohammad Rahnama, MD
Internal Medicine · Parkville, MDNPI 1952458739
Payments from drug & device makers
Across 1,451 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- GSK$2K
- Amgen$912
- plus $14K from 54 others
What the payments were for
- Food & beverage$26,71099%
- Education$2631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$252
- NEXLIZET$250
- NEXLETOL$250
- DEXCOM G6 TRANSMITTER$245
- Ozempic$241
- NURTEC ODT$232
- UBRELVY$228
- LINZESS$141
- VIBERZI$141
- DEXCOM G7 GSS (161)$140
- DEXCOM STELO GLUCOSE BIOSENSOR$140
- FreeStyle Libre Pro$131
- TRELEGY ELLIPTA$122
- RYBELSUS$122
- AIMOVIG$122
- BREZTRI$115
- VRAYLAR$115
- Vascepa$110
- FREESTYLE LIBRE 3$109
- ASNIS$108
How this compares
$26,973 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $163,027 |
| EliquisApixaban | 118 | $130,552 |
| RybelsusSemaglutide | 61 | $120,314 |
| JardianceEmpagliflozin | 95 | $96,805 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $96,067 |
| FarxigaDapagliflozin Propanediol | 75 | $90,470 |
| TrulicityDulaglutide | 35 | $66,499 |
| JanuviaSitagliptin Phosphate | 44 | $55,535 |
| XareltoRivaroxaban | 55 | $54,695 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $29,982 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $26,487 |
| RexultiBrexpiprazole | 16 | $25,232 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $22,471 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $18,909 |
| LinzessLinaclotide | 23 | $17,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,317 | $283,341182 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,523 | $141,464141 claims |
| PfizerEliquis, Paxlovid | $817 | $136,109129 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $2,149 | $113,143109 claims |
| Boehringer IngelheimJardiance | $905 | $96,80595 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,708 | $83,82050 claims |
| MerckJanuvia | $454 | $55,53544 claims |
| Johnson & JohnsonXarelto | $564 | $54,69555 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $291 | $25,23216 claims |
| AbbVieLinzess | $4,022 | $17,81723 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $672 | $11,03911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Parkville
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.